Molecular Motors: Myosin

Myosin is a mechanoenzyme: an ATPase whose catalytic cycle is mechanically coupled to a cytoskeletal track. Every myosin molecule has a conserved motor domain (the "head"), roughly 800 amino acids, containing an ATP-binding pocket and an actin-binding surface. Adjacent to the head is a neck or lever-arm region, typically built from IQ motifs that bind calmodulin or myosin light chains. The neck's job is amplification: a small rearrangement of a few angstroms at the nucleotide pocket is mechanically transmitted and magnified into a swing of several nanometers at the far end of the lever arm. Beyond the neck lies the tail, which is the most variable part of the molecule and determines the myosin's biological role — self-assembly into bipolar thick filaments (myosin II), cargo-binding domains for vesicles and organelles (myosin V), or membrane-binding motifs (myosin I). The superfamily is organized by phylogenetic analysis of motor-domain sequence into more than 35 classes, denoted by Roman numerals (myosin I through myosin XXXVI and beyond, with new classes still occasionally proposed). Despite this diversity, every class shares the same core ATPase chemistry, discovered originally in skeletal muscle myosin II, and every myosin moves toward the plus (barbed) end of actin filaments — with the notable and instructive exception of myosin VI, which moves toward the minus (pointed) end, achieved by a unique insertion that redirects the lever-arm swing. Two functional strategies define how myosins are used. Non-processive motors like myosin II detach from actin during most of their cycle and generate force only fleetingly; they function only in large ensembles (hundreds within a thick filament) so that at any instant some heads are always attached, sustaining continuous force or contraction. Processive motors like myosin V remain attached to actin for the majority of their cycle, allowing a single dimeric molecule to walk continuously for many steps without falling off — essential for a lone motor carrying a vesicle over micrometers of cytoplasm. This distinction — ensemble force generators versus single-molecule cargo carriers — is one of the most important organizing ideas in motor biology, and it recurs when comparing myosin to the microtubule motors kinesin and dynein.

The chemomechanical cycle. The myosin ATPase cycle is best understood as a four-state cycle linking nucleotide state to actin affinity and lever-arm angle. 1. Rigor state. In the absence of ATP, myosin binds actin with very high affinity — the "rigor" configuration (named for rigor mortis, when ATP is depleted and all myosin heads lock onto actin). 2. ATP binding and detachment. ATP binds the nucleotide pocket, triggering a conformational change in the actin-binding cleft that sharply lowers actin affinity. Myosin detaches from the filament within milliseconds. 3. Hydrolysis and re-cocking. ATP is hydrolyzed to ADP and inorganic phosphate (Pi), both of which remain bound to the head. This hydrolysis drives the "recovery stroke": the lever arm rotates back into a cocked, high-energy conformation, like drawing back a spring-loaded hammer. The myosin head, still detached, now weakly rebinds actin. 4. Power stroke. Weak binding to actin triggers phosphate release. This is the key mechanochemical trigger: Pi release converts the weakly bound state into a strongly bound state and simultaneously drives the power stroke — the lever arm swings through its working angle, pulling the attached actin filament past the myosin. ADP is released afterward, returning the head to the rigor state, ready for the next ATP. The force-generating event is thus phosphate release, not ATP hydrolysis itself — hydrolysis merely stores the energy by re-cocking the lever arm; release of the products is what is mechanically coupled to force. This ordering — weak-binding states while nucleotide-bound (ATP or ADP·Pi), strong-binding states after phosphate loss — is the universal grammar of the myosin cycle and explains why ATP depletion causes irreversible rigor rather than relaxation.

Amplification by the lever arm. Structural studies (below) show the actual rotation at the nucleotide pocket is small, but the neck region — stiffened by bound light chains that act as a rigid lever — converts this into a swing of the lever-arm tip through roughly 60–70°, translating into a working stroke of 5–10 nm for muscle myosin II, and up to ~36 nm for myosin V (matched to the actin helical repeat, permitting hand-over-hand walking).

Ensemble contraction in muscle. In a sarcomere, myosin II tails self-assemble into bipolar thick filaments, with hundreds of heads projecting outward in each direction toward the plus ends of the interdigitating thin (actin) filaments. Because each head spends only ~5% of its cycle strongly bound (a low duty ratio), a single head could never sustain continuous tension — but with hundreds of heads per filament cycling asynchronously, at any moment some fraction is always attached and pulling, producing smooth, sustained force. This is why muscle myosin must work in huge cooperative arrays.

Processive transport in myosin V. Myosin V is a two-headed (dimeric) motor with a much higher duty ratio (~50–70%), so at least one head is bound to actin at all times. The two heads coordinate in hand-over-hand stepping: while the rear head detaches, hydrolyzes ATP, and re-cocks, the front head remains bound, and intramolecular strain biases the detached head to swing forward and rebind 36 nm ahead — matching the actin filament's helical pseudo-repeat so the motor walks in a straight line along a single actin strand rather than spiraling around the filament.

Regulation. In smooth muscle and non-muscle cells, myosin II activity is controlled by phosphorylation of the regulatory light chain by myosin light-chain kinase (activated by Ca²⁺–calmodulin), switching the head between an inactive folded conformation and an active extended one. In striated (skeletal and cardiac) muscle, regulation instead occurs on the actin side: the troponin–tropomyosin complex blocks myosin-binding sites on actin until Ca²⁺ released from the sarcoplasmic reticulum binds troponin C, causing tropomyosin to shift and expose the sites — this is the molecular basis of excitation–contraction coupling.

The sliding filament model (1954). Before the 1950s, the dominant idea was that muscle contraction involved actual folding or coiling of a single type of contractile protein filament. Two independent groups — Hugh Huxley and Jean Hanson at MIT/King's College, and Andrew Huxley and Rolf Niedergerke at Cambridge — published back-to-back papers in Nature in 1954 that overturned this. Using phase-contrast and interference light microscopy on living, intact muscle fibers, they measured the widths of the A-band (containing thick filaments) and I-band (containing only thin filaments) during contraction at different degrees of stretch. The critical, non-obvious finding: the A-band width stayed constant during contraction, while the I-band shortened, and the region of filament overlap increased. If filaments themselves were shrinking, the A-band should have shrunk too. Instead, the data showed two sets of filaments of fixed length sliding past each other, telescoping into the space vacated by the shortening I-band. This directly established that contraction is filament sliding, not filament coiling or folding — the founding observation of the sliding filament model, later refined by X-ray diffraction studies (also led by Hugh Huxley) that confirmed constant filament lengths and periodic cross-bridges linking thick to thin filaments.

In vitro motility assays (1980s). The sliding filament model told you filaments move relative to each other but not that myosin alone, without any other cellular machinery, was sufficient to generate this motion. James Spudich and Sivaramakrishnan Kron (1986) devised the in vitro motility assay: myosin molecules were adsorbed onto a glass coverslip, and fluorescently labeled actin filaments (rhodamine–phalloidin-stained) were then added along with ATP. Under a fluorescence microscope, the actin filaments were observed gliding across the myosin-coated surface at velocities of roughly 2–8 µm/s, matching physiological shortening velocities of muscle, and this movement was strictly ATP-dependent — no ATP, no motion; adding the non-hydrolyzable ATP analog AMP-PNP locked the filaments in place (rigor). This was the crucial reductionist proof that purified myosin and actin alone, with ATP, are sufficient to reconstitute directed force generation — no other muscle proteins were required.

Optical trap single-molecule measurements (1994). James Spudich, Jeff Finer, and Robert Simmons used a dual-beam optical trap to hold a single actin filament taut between two polystyrene beads and lower it onto a single myosin molecule fixed to a third bead on the coverslip surface. This let them detect the mechanical output of one myosin head interacting with actin one ATP hydrolysis cycle at a time. They measured a single-molecule displacement (working stroke) of about 11 nm and forces on the order of 3–4 piconewtons per interaction — the first direct, single-molecule confirmation of the discrete step sizes and forces predicted by the lever-arm hypothesis.

The crystal structure (1993). Ivan Rayment and colleagues at the University of Wisconsin solved the first atomic-resolution crystal structure of the myosin motor domain (from chicken skeletal muscle) bound to nucleotide analogs. This structure revealed the actin-binding cleft, the nucleotide pocket, and — crucially — the elongated, α-helical neck region stabilized by bound light chains, exactly the lever-arm architecture predicted on functional grounds. Subsequent structures captured different nucleotide states (rigor-like, pre-power-stroke, and post-power-stroke conformations), directly visualizing the swing of the lever arm and providing the structural proof of the swinging-lever-arm mechanism inferred from the mechanical and kinetic experiments above.

Example 1 — Calculating shortening velocity from step size and cycling rate. A skeletal muscle myosin head has a working stroke of 8 nm and, at a given ATP concentration, hydrolyzes ATP (and thus completes one full cross-bridge cycle) at a rate of 20 cycles per second (this rate, together with duty ratio, sets how quickly the ensemble can move). If we treat an idealized single continuously-cycling head: velocity = step size × cycling rate = 8 nm × 20 s⁻¹ = 160 nm/s per head Scaled up: a half-sarcomere is about 1 µm long, so at this velocity a sarcomere could, in principle, fully shorten in roughly 1000 nm ÷ 160 nm/s ≈ 6 seconds if only one myosin acted alone and unopposed — far slower than real muscle, whose fibers can shorten a full sarcomere-length fraction in tens of milliseconds. The resolution is that hundreds of myosin heads act in parallel and asynchronously within each thick filament; because muscle myosin has a low duty ratio (~5%), any single head only occasionally contributes a stroke, but the ensemble average lets a fiber achieve macroscopic shortening velocities of several µm/s to tens of µm/s depending on fiber type (slow type I versus fast type IIb fibers), consistent with the ATPase-rate differences that physiologically distinguish "slow" and "fast" muscle fibers (slow fibers cycle ATP roughly an order of magnitude slower than fast fibers, matching their lower maximal shortening velocity, per the classic force–velocity relationship of A.V. Hill).

Example 2 — Diagnosing a myosin mutation from a clinical/genetic scenario. A 22-year-old competitive athlete collapses during a match and is found on autopsy to have asymmetric thickening of the interventricular septum, disorganized ("myofiber disarray") cardiac muscle architecture, and a family history of two first-degree relatives who died suddenly before age 40. Genetic testing reveals a heterozygous missense mutation in MYH7, the gene encoding β-myosin heavy chain, the principal myosin II isoform expressed in cardiac ventricular muscle and slow skeletal fibers. Reasoning through the mechanism: MYH7 mutations causing hypertrophic cardiomyopathy (HCM) commonly map to the motor domain (affecting ATPase kinetics or actin affinity) or to the lever-arm/light-chain-binding region (affecting stroke size or ensemble force production). Many HCM-causing mutations are now understood, from single-molecule and ensemble mechanical studies, to increase the intrinsic force or duty ratio of individual myosin heads, or increase the fraction of heads recruited from a low-force "super-relaxed" (SRX) state into the actively cycling state — producing hypercontractility at the sarcomere level. Chronic hypercontraction triggers a compensatory hypertrophic and fibrotic remodeling response, producing the thickened, disorganized septum characteristic of HCM and creating a substrate for fatal arrhythmia — explaining the exercise-triggered sudden death pattern. Because the mutation is heterozygous, the patient's sarcomeres contain a mixture of mutant and wild-type myosin (a "poison polypeptide" effect diluted across thick filaments, since each filament incorporates hundreds of myosin molecules from both alleles), which is why the disease, while dominant, has variable severity and age of onset across carriers — consistent with real-world genetic heterogeneity in HCM pedigrees. This clinical logic directly motivates the modern pharmacological strategy of myosin inhibitors (see "Where this matters today").

Hugh Esmor Huxley (1924–2013) trained as a physicist at Cambridge, working on radar during World War II, before turning to biophysics and applying X-ray diffraction and electron microscopy to the problem of muscle structure — bringing a physicist's quantitative rigor to what had been a largely descriptive field of histology. Working initially at MIT and later at Cambridge's Laboratory of Molecular Biology and Brandeis University, Huxley combined light microscopy of live fibers with X-ray diffraction of both resting and contracting muscle to build the structural case for sliding filaments and, later, for the swinging cross-bridge itself. His independent co-discovery, alongside the physiologist Andrew Huxley (no relation) working with Rolf Niedergerke, is a classic case of convergent evidence from different methods (interference microscopy versus tension/length physiology) arriving at the same structural conclusion in the same issue of Nature.

Cardiac drugs targeting myosin directly. Mavacamten (approved by the FDA in 2022) is a small-molecule allosteric inhibitor of cardiac β-myosin (MYH7) that reduces the number of myosin heads available to form force-generating cross-bridges, directly counteracting the hypercontractility caused by HCM-associated mutations described above — one of the first drugs designed to modulate a molecular motor's mechanochemical cycle rather than a receptor or channel. Conversely, omecamtiv mecarbil, a cardiac myosin activator, has been trialed to improve contractility in heart failure with reduced ejection fraction by slowing myosin's release from the strongly bound (force-holding) state.

Genetic disease. Beyond MYH7-linked cardiomyopathy, mutations in unconventional myosins cause a range of human diseases: MYO7A mutations cause Usher syndrome (combined deafness and blindness, reflecting myosin VIIa's role in stereocilia and photoreceptor maintenance); MYH9 mutations cause a spectrum of platelet and kidney disorders (MYH9-related disease); and myosin light-chain kinase and phosphatase pathways are targets in the pharmacology of vascular smooth muscle tone and hypertension.

Biotechnology. In vitro motility assays and single-molecule optical trap techniques, originally developed to study myosin, became foundational tools now applied across the whole motor-protein field, including for the microtubule-based motors Molecular Motors: Kinesin and Dynein. Engineered myosin motors are used in nanotechnology as molecular "shuttles" to transport cargo along patterned actin tracks in lab-on-a-chip devices.

Agriculture and food science. Post-mortem myosin–actin interactions (rigor mortis and its resolution) directly determine meat tenderness, and understanding the calcium-dependent regulation of the actomyosin cross-bridge cycle informs livestock handling and meat-aging protocols in the food industry.

Basic cell biology. Myosin II drives cytokinesis by constricting the contractile ring, and myosin-generated cortical tension shapes epithelial morphogenesis during development — connecting this single molecular motor to processes central to understanding Cell Division and tissue architecture, and to the broader logic of how the Cytoskeleton organizes cellular mechanics.

Ask the tutor: How does the myosin lever-arm mechanism compare mechanistically to the way kinesin and dynein generate stepping motion on microtubules?